177 related articles for article (PubMed ID: 33303645)
21. Proviral integration site for Moloney murine leukemia virus 1, but not phosphatidylinositol-3 kinase, is essential in the antiapoptotic signaling cascade initiated by IL-5 in eosinophils.
Andina N; Didichenko S; Schmidt-Mende J; Dahinden CA; Simon HU
J Allergy Clin Immunol; 2009 Mar; 123(3):603-11. PubMed ID: 19152965
[TBL] [Abstract][Full Text] [Related]
22. New potent and selective inhibitor of Pim-1/3 protein kinases sensitizes human colon carcinoma cells to doxorubicin.
Moreau P; Dezhenkova LG; Anizon F; Nauton L; Thery V; Liang S; Kaluzhny DN; Shtil AA
Anticancer Agents Med Chem; 2014; 14(9):1228-36. PubMed ID: 25175798
[TBL] [Abstract][Full Text] [Related]
23. The survival kinases Akt and Pim as potential pharmacological targets.
Amaravadi R; Thompson CB
J Clin Invest; 2005 Oct; 115(10):2618-24. PubMed ID: 16200194
[TBL] [Abstract][Full Text] [Related]
24. New Quinoxaline Derivatives as Dual Pim-1/2 Kinase Inhibitors: Design, Synthesis and Biological Evaluation.
Oyallon B; Brachet-Botineau M; Logé C; Robert T; Bach S; Ibrahim S; Raoul W; Croix C; Berthelot P; Guillon J; Pinaud N; Gouilleux F; Viaud-Massuard MC; Denevault-Sabourin C
Molecules; 2021 Feb; 26(4):. PubMed ID: 33562106
[TBL] [Abstract][Full Text] [Related]
25. Targeting PIM kinases in cancer therapy: An update on pharmacological small-molecule inhibitors.
Chen S; Yang Y; Yuan Y; Bo Liu
Eur J Med Chem; 2024 Jan; 264():116016. PubMed ID: 38071792
[TBL] [Abstract][Full Text] [Related]
26. Resveratrol suppresses gastric cancer cell proliferation and survival through inhibition of PIM-1 kinase activity.
Kim S; Kim W; Kim DH; Jang JH; Kim SJ; Park SA; Hahn H; Han BW; Na HK; Chun KS; Choi BY; Surh YJ
Arch Biochem Biophys; 2020 Aug; 689():108413. PubMed ID: 32473133
[TBL] [Abstract][Full Text] [Related]
27. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
[TBL] [Abstract][Full Text] [Related]
28. PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.
Warfel NA; Sainz AG; Song JH; Kraft AS
Mol Cancer Ther; 2016 Jul; 15(7):1637-47. PubMed ID: 27196781
[TBL] [Abstract][Full Text] [Related]
29. Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.
Chatterjee S; Chakraborty P; Daenthanasanmak A; Iamsawat S; Andrejeva G; Luevano LA; Wolf M; Baliga U; Krieg C; Beeson CC; Mehrotra M; Hill EG; Rathmell JC; Yu XZ; Kraft AS; Mehrotra S
Clin Cancer Res; 2019 Feb; 25(3):1036-1049. PubMed ID: 30327305
[TBL] [Abstract][Full Text] [Related]
30. Pim Kinases Promote Migration and Metastatic Growth of Prostate Cancer Xenografts.
Santio NM; Eerola SK; Paatero I; Yli-Kauhaluoma J; Anizon F; Moreau P; Tuomela J; Härkönen P; Koskinen PJ
PLoS One; 2015; 10(6):e0130340. PubMed ID: 26075720
[TBL] [Abstract][Full Text] [Related]
31. PIM Kinases Promote Survival and Immune Escape in Primary Mediastinal Large B-Cell Lymphoma through Modulation of JAK-STAT and NF-κB Activity.
Szydłowski M; Dębek S; Prochorec-Sobieszek M; Szołkowska M; Tomirotti AM; Juszczyński P; Szumera-Ciećkiewicz A
Am J Pathol; 2021 Mar; 191(3):567-574. PubMed ID: 33307035
[TBL] [Abstract][Full Text] [Related]
32. PIM kinases: an overview in tumors and recent advances in pancreatic cancer.
Xu J; Zhang T; Wang T; You L; Zhao Y
Future Oncol; 2014 Apr; 10(5):865-76. PubMed ID: 24799066
[TBL] [Abstract][Full Text] [Related]
33. Phosphorylation of Notch1 by Pim kinases promotes oncogenic signaling in breast and prostate cancer cells.
Santio NM; Landor SK; Vahtera L; Ylä-Pelto J; Paloniemi E; Imanishi SY; Corthals G; Varjosalo M; Manoharan GB; Uri A; Lendahl U; Sahlgren C; Koskinen PJ
Oncotarget; 2016 Jul; 7(28):43220-43238. PubMed ID: 27281612
[TBL] [Abstract][Full Text] [Related]
34. [The Pim family of protein kinases: structure, functions and roles in hematopoietic malignancies].
Zhukova IuN; Alekseeva MG; Zakharevich NV; Shtil' AA; Danilenko VN
Mol Biol (Mosk); 2011; 45(5):755-64. PubMed ID: 22393773
[TBL] [Abstract][Full Text] [Related]
35. [Drug resistance mediated by survival- and growth-promoting signaling pathways].
Fujita N
Gan To Kagaku Ryoho; 2009 Apr; 36(4):567-71. PubMed ID: 19381028
[TBL] [Abstract][Full Text] [Related]
36. The PIM kinases in hematological cancers.
Alvarado Y; Giles FJ; Swords RT
Expert Rev Hematol; 2012 Feb; 5(1):81-96. PubMed ID: 22272708
[TBL] [Abstract][Full Text] [Related]
37. PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.
Luszczak S; Kumar C; Sathyadevan VK; Simpson BS; Gately KA; Whitaker HC; Heavey S
Signal Transduct Target Ther; 2020 Jan; 5(1):7. PubMed ID: 32296034
[TBL] [Abstract][Full Text] [Related]
38. Use of regulators and inhibitors of Pim-1, a serine/threonine kinase, for tumour therapy (review).
Liang C; Li YY
Mol Med Rep; 2014 Jun; 9(6):2051-60. PubMed ID: 24737044
[TBL] [Abstract][Full Text] [Related]
39. Insulin receptor substrate 1 is a substrate of the Pim protein kinases.
Song JH; Padi SK; Luevano LA; Minden MD; DeAngelo DJ; Hardiman G; Ball LE; Warfel NA; Kraft AS
Oncotarget; 2016 Apr; 7(15):20152-65. PubMed ID: 26956053
[TBL] [Abstract][Full Text] [Related]
40. Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition.
Iqbal A; Eckerdt F; Bell J; Nakano I; Giles FJ; Cheng SY; Lulla RR; Goldman S; Platanias LC
Oncotarget; 2016 May; 7(22):33192-201. PubMed ID: 27120806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
